Sei Investments Co. lessened its stake in shares of Qiagen NV (NASDAQ:QGEN) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 233,977 shares of the company’s stock after selling 8,636 shares during the quarter. Sei Investments Co.’s holdings in Qiagen were worth $7,237,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in QGEN. Atlanta Capital Management Co. L L C boosted its position in shares of Qiagen by 210.1% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock worth $41,400,000 after purchasing an additional 890,454 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Qiagen by 163.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 844,529 shares of the company’s stock worth $26,326,000 after purchasing an additional 523,453 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Qiagen by 127.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 652,285 shares of the company’s stock worth $20,521,000 after purchasing an additional 365,732 shares in the last quarter. FNY Partners Fund LP boosted its position in shares of Qiagen by 644.2% during the 4th quarter. FNY Partners Fund LP now owns 323,022 shares of the company’s stock worth $9,991,000 after purchasing an additional 279,619 shares in the last quarter. Finally, Vident Investment Advisory LLC boosted its position in shares of Qiagen by 70.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 385,068 shares of the company’s stock worth $12,130,000 after purchasing an additional 158,694 shares in the last quarter. 62.23% of the stock is currently owned by institutional investors.
Shares of Qiagen NV (QGEN) opened at $33.82 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59. Qiagen NV has a fifty-two week low of $27.74 and a fifty-two week high of $36.34. The firm has a market cap of $7,810.00, a PE ratio of 198.94, a P/E/G ratio of 1.93 and a beta of 1.03.
A number of equities analysts have recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Qiagen in a research report on Monday, January 29th. They set a “buy” rating and a $39.00 price objective on the stock. BidaskClub raised shares of Qiagen from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Cowen restated a “hold” rating and issued a $33.00 target price on shares of Qiagen in a report on Friday, November 3rd. Morgan Stanley upped their target price on shares of Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Finally, Commerzbank restated a “buy” rating on shares of Qiagen in a report on Thursday, February 1st. Eight equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $35.33.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3228577/qiagen-nv-qgen-shares-sold-by-sei-investments-co.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.